Thrombin's central role in angiogenesis and pathophysiological processes

European Cytokine Network

Volumn 20, Issue 4, 2009, Pages 171-179

  Tsopanoglou, Nikos E ^a   Maragoudakis, Michael E ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Angiogenesis; Apoptosis; Coagulation cascade; Endothelial cells; Proteinase activated receptor 1; Thrombin

Indexed keywords

ANGIOGENESIS INHIBITOR; CELL SURFACE RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRIN; FIBRINOGEN; GAMMA THROMBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEINASE ACTIVATED RECEPTOR 1; REACTIVE OXYGEN METABOLITE; RWJ 56110; SCH 79797; THROMBIN; THROMBOPLASTIN; THROMBOSPONDIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APOPTOSIS; BLOOD CLOTTING; CANCER GROWTH; CANCER THERAPY; CELL ADHESION; CELL CYCLE ARREST; CELL INTERACTION; CELL MIGRATION; CELL PROTECTION; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; ENZYME ACTIVATION; HEMOSTASIS; HUMAN; INFLAMMATION; ISCHEMIA; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REPERFUSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; TUMOR CELL; WOUND HEALING;

ANIMALS; APOPTOSIS; BLOOD COAGULATION; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, PAR-1; THROMBIN;

EID: 72249120877     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2009.0166     Document Type: Review

References (135)

1. Di Cera E. Thrombin interactions. Chest 2003; 124: 11S.
2. Esmon CT. The protein C pathway. Chest 2003; 124: 26S.
3. Gettins PG. Serpin structure, mechanism, and function. Chem Rev 2002; 102: 4751.
4. Olson ST, Chuang YJ. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med 2002; 12: 331.
5. Tollefsen DM. Heparin cofactor II modulates the response to vascular injury. Arterioscler Thromb Vasc Biol 2007; 27: 454.
6. Coughlin SR. Thrombin signaling and protease-activated receptors. Nature 2000; 407: 1921.
7. Vu T-K, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057.
8. Kuliopoulos A, Civic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR-1 thrombin receptor: kinetics, sites of truncation and implications for thrombolutic therapy. Biochemistry 1999; 38: 4572. (Pubitemid 129514727)
9. Riewald M, Kravchenko VV, Petrovan RJ, Mueller B. M, Ruf W. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood 2001; 97: 3109.
10. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease-activated receptor 1 by the protein C pathway. Science 2002; 296: 1880. (Pubitemid 34596276)
11. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopoulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120: 303. (Pubitemid 40222426)
12. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690. (Pubitemid 28389797)
13. Lafleur MA, Hollenberg MD, Atkinson SJ, Knauper V, Murphy G, Edwards DR. Activation of pro(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem J 2001; 357: 107. (Pubitemid 32642908)
14. Bar Shavit R, Kahn A, Mudd MS, Wilner GD, Mann KG, Fenton JW. Localization of a chemotactic domain in human thrombin. Biochemistry 1984; 23: 397.
15. Bar-Shavit R, Kahn AJ, Mann KG, Wilner GD. Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci USA 1986; 83: 976. (Pubitemid 16086396)
16. Glenn KC, Frost GH, Bergmann JS, Carney DH. Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis. Pept Res 1988; 1: 65.
17. Senior RM, Skogen WF, Griffin GL, Wilner GD. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Invest 1986; 77: 1014.
18. Kay AB, Pepper DS, Edwart MR. Generation of chemotactic activity for leukocytes by the action of thrombin on human fibrinogen. Nat New Biol 1973; 243: 56.
19. Kay AB, Pepper DS, McKenzie R. The identification of fibrino-peptide B as a chemotactic agent derived from human fibrinogen. Br J Haematol 1974; 27: 669.
20. Dvorak HF. Angiogenesis: update 2005. J Thromb Haemost 2005; 3: 1835.
21. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin and cancer. Chest 2003; 124: 58S.
22. Eming SA, Brachvogel B, Odorisio T, Koch M. Regulation of angiogenesis: wound healing as a model. Proq Histochem Cytochem 2007; 42: 115. (Pubitemid 350016248)
23. Wojtukiewicz MZ, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Sem Thromb Haemost 2004; 30: 5. (Pubitemid 38457297)
24. Daubie V, Pochet R, Houard S, Philippart P. Tissue factor: a minireview. J Tissue Eng Regen Med 2007; 1: 161.
25. Swada M, Miyake S, Ahdama S, et al. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999; 79: 472. (Pubitemid 29046221)
26. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83: 164. (Pubitemid 30411712)
27. Nakasaki T, Wada HM, Shigemori C, et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002; 69: 247. (Pubitemid 34259846)
28. Guan M, Jin J, Su B, Liu WW, Lu Y. Tissue factor expression and angiogenesis in human glioma. Clin Biochem 2002; 35: 321. (Pubitemid 34804904)
29. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320. (Pubitemid 24286478)
30. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999; 96: 8663. (Pubitemid 29354848)
31. Versteeg HH, RufW. Emerging insights in tissue factor dependent signaling events. Semin Thromb Haemost 2006; 32: 24.
32. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10: 502. (Pubitemid 38667909)
33. Amirkhosravi A, Meyer T, Amaya M, et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Sem Thromb Hemost 2007; 33: 643. (Pubitemid 350157007)
34. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 2004; 30: 31.
35. Sierko E, Wojtukiewicz MZ, Kisiel W. The role of tissue factor pathway inhibitor-2. Sem Thromb Haemost 2007; 33: 653.
36. Yanamandra N, Kondraganti S, Gondi CS, et al. Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer 2005; 115: 998. (Pubitemid 40791841)
37. Ivanciu L, Gerard RD, Tang H, Lupu F, Lupu C. Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 310. (Pubitemid 46143045)
38. Xu Z, Maiti D, Kisiel W, Duh EL. Tissue factor pathway inhibitor-2 is up-regulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: 2819. (Pubitemid 44777303)
39. Suzuki K, Hayashi T. Protein C and its inhibitor in malignancy. Semin Thromb Haemost 2007; 33: 667.
40. Ushiba M, Okajima K, Oike Y, et al. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ Res 2004; 95: 34. (Pubitemid 38931833)
41. Asanuma K, Yoshikawa T, Hayashi T, et al. Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity. Int J Cancer 2007; 121: 955.
42. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65: 3967.
43. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin anti-thrombin. Science 1999; 285: 1926. (Pubitemid 129515517)
44. Lee TH, Rhim T, Kim SS. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J Biol Chem 1998; 273: 28805. (Pubitemid 28507571)
45. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521.
46. O'Reilly MS. Antiangiogenic antithrombin. Sem Thromb Hemost 2007; 33: 660.
47. Kim TH, Kim E, Yoon D, Kim J, Rhim TY, Kim SS. Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases. Angiogenesis 2002; 5: 191. (Pubitemid 36687522)
48. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Sem Thromb Haemost 2004; 30: 63.
49. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol Cell Physiol 1993; 264: C1302. (Pubitemid 23158838)
50. Haralabopoulos GC, Grant DS, Klienman HK, Maragoudakis ME. Thrombin promotes endothelial cell alignment in matrigel in vitro and angiogenesis in vivo. Am J Physiol Cell Physiol 1997; 273: C239.
51. Moser M, Patterson C. Thrombin and vascular development. Arterioscler Thromb Vasc Biol 2003; 23: 922.
52. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81: 695.
53. Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes & Development 1995; 9: 2020.
54. Caunt M, Huang Y, Brooks P, Karpatkin S. Thrombin induces neoangiogenesis in the chick chorioallontoic membrane. J Thromb Haemost 2003; 1: 2097.
55. Huang Y-Q, Li J-J, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 2001; 86: 1094.
56. Huang Y-Q, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002; 99: 1646. (Pubitemid 34533037)
57. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis: potentiation of vascular endothelial growth factor activity on the endothelial cells by up-regulation of its receptors. J Biol Chem 1999; 274: 23969.
58. Caunt M, Hu L, Tang T, Brooks P, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res 2006; 66: 4125.
59. Dupuy E, Habib A, Lebret M, Yang R, Levy-Toledano S, Tobelem G. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-I alpha. J Thromb Haemost 2003; 1: 1096.
60. phox-containing NAPDH oxidase. Circ Res 2001; 89: 47.
61. BelAida RS, Djordjevic T, Bonello S, et al. Redox-sensitive regulation of HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells. Biol Chem 2004; 385: 249. (Pubitemid 38679070)
62. Olivot J-M, Estebanell E, Lafay M, Brohard B, Aiach M, Rendu F. Thrombomodulin prolongs thrombin-induced extracellular signal-regulated kinase phosphorylation and nuclear retention in endothelial cells. Circ Res 2001; 88: 681. (Pubitemid 32378137)
63. Zania P, Papaconstantinou M, Flordellis CS, Maragoudakis ME, Tsopanoglou NE. Thrombin mediates mitogenesis and survival of human endothelial cells through distinct mechanisms. Am J Physiol Cell Physiol 2008; 294: C1215.
64. Martorell L, Martionez-Gonzalez J, Crespo J, Calvayrac O, Badimon L. Neuro-derived orphan receptor-1 (NOR-1) is induced by thrombin and mediates endothelial cell growth. J Thromb Haemost 2007; 5: 1766. (Pubitemid 47091422)
65. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis: inhibition of attachment of endothelial cells on basement membrane components. Angiogenesis 1998; 1: 192.
66. Zucker S, Conner C, DiMassimo BI, et al. Thrombin induces the activation of progelatinase A in vascular endothelial cells. J Biol Chem 1995; 270: 23730.
67. Fernandez-Patron C, Zhang Y, Radomski MW, Hollenberg MD, Davidge ST. Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase. Thromb Haemost 1999; 82: 1353. (Pubitemid 29473806)
68. Tsopanoglou NE, Andriopoulou P, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis: involvement of ανβ3 integrin. Am J Physiol Cell Physiol 2002; 283: C1501. (Pubitemid 35178442)
69. Zania P, Gourni D, Aplin AC, et al. Parstatin, the cleaved peptide on Proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis. J Pharmacol Exp Ther 2009; 328: 378.
70. Strande JL, Widlansky ME, Tsopanoglou NE, et al. Parstatin: a cryptic peptide involved in cardioprotection after ischemia and reperfusion injury. Cardiovasc Res 2009; 83: 325.
71. Smadja DM, Bieche I, Uzan G, et al. PAR-1 activation on human late endothelial progenitor cells enhances angiogenesis in vitro with upregulation of the SDF-1/CXCR4 system. Arteriol Thromb Vasc Biol 2005; 25: 2321. (Pubitemid 41552649)
72. Tarzami ST, Wang G, Li W, Green L, Singh JP. Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells. J Thromb Haemost 2005; 4: 656.
73. Smadja DM, Laurendeau I, Avignon C, Vidaud M, Aiach M, Gaussem P. The angiopoietin pathway is modulated by PAR-1 activation on human endothelial progenitor cells. J Thromb Haemost 2006; 5: 2051. (Pubitemid 44226788)
74. Chen D, Abrahams JM, Smith LM, McVey JH, Lechler RI, Dorling A. Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors. Blood 2008; 111: 4155.
75. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 1998; 125: 1252. (Pubitemid 28542534)
76. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000; 96: 4216.
77. Rhee JS, Black M, Schubert U, et al. The functional role of blood platelet components in angiogenesis. Thromb Haemost 2004; 92: 394. (Pubitemid 39177413)
78. Kisucka J, Butterfield CE, Duda DG, et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006; 103: 855. (Pubitemid 43212187)
79. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663. (Pubitemid 27053690)
80. Verheul HMW, Hoekman K, Luykx-de Bakker S, et al. Platelet transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187. (Pubitemid 28133134)
81. Wartiovaara U, Salven P, Mikkola Heta I. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998; 80: 171. (Pubitemid 28353517)
82. Friesel R, Maciag T. Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling. Thromb Haemost 1999; 82: 748.
83. Guo P, Hu B, Gu W, et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003; 162: 1083. (Pubitemid 36350654)
84. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressordependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624. (Pubitemid 20351533)
85. Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 2003; 139: 329. (Pubitemid 36760365)
86. Ma L, Perini R, McKnight W, Klein A, Hollenberg MD, Wallace JL. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 2005; 102: 216. (Pubitemid 40094455)
87. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003; 1: 1655.
88. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005; 67: 30. (Pubitemid 40798290)
89. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005; 113: 752. (Pubitemid 40101256)
90. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998; 101: 40. (Pubitemid 28058901)
91. Steinhoff M, Buddenkotte J, Shpacovitch V, et al. Proteinase-activated receptors: thansducers of proteinase-mediated signalling in inflammation and immune response. Endocr Rev 2005; 26: 1. (Pubitemid 40209385)
92. Vergnolle N, Derian CK, D'Andrea MR, Steinhoff M, Andrade- Gordon P. Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J Immunol 2002; 169: 1467. (Pubitemid 34809192)
93. Malik AB, Fenton JW. Thrombin-mediated increase in vascular endothelial permeability. Sem Thromb Hemost 1992; 18: 193.
94. Razin E, Marx G. Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J Immunol 1984; 133: 3282. (Pubitemid 15216505)
95. Bizios R, Lai L, Fenton JW, Malik AB. Thrombin-induced chemotaxis and aggregation of neutrophils. J Cell Physiol 1986; 128: 485.
96. Toothill VJ, van Mourik JA, Niewenhuis HK, Metzelaar MJ, Rearson JD. Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells. J Immunol 1990; 145: 283.
97. Kranzhofer R, Clinton SK, Ishii K, Coughlin SR, Fenton JW, Libby P. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. Circ Res 1996; 79: 286. (Pubitemid 26255881)
98. Stankova J, Rola-Pleszczynski M, D'Orleans-Juste P. Endothelin 1 and thrombin synergistically stimulate IL-6 mRNA expression and protein production in human umbilical vein endothelial cells. J Cardiovasc Pharmacol 1995; 26: S505.
99. Ueno A, Murakami K, Yamanouchi K, Watanabe M, Kondo T. Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells. Immunology 1996; 88: 76. (Pubitemid 26166379)
100. Chen D, Carpenter A, Abrahams J, et al. Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med 2008; 205: 1739.
101. Laurens N, Koolwijk P, Maat MPM. Fibrin structure and wound healing. J Thromb Haemost 2006; 4: 932.
102. Koolwijk P, van Erck MG, de Vree WJ, et al. Cooperative effect of TNF-alpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132: 1177. (Pubitemid 3039145)
103. Medved L, Tsurupa G, Yakovlev S. Conformational changes upon conversion of fibrinogen into fibrin: the mechanisms of exposure of cryptic sites. Ann NY Acad Sci 2001; 936: 185. (Pubitemid 32613904)
104. Martinez J, Ferber A, Bach TL, Yaen CH. Interaction of fibrin with VE-cadherin. Ann N Y Acad Sci 2001; 936: 386.
105. Clark RA, Tonnesen MG, Gailit J, Cheresh DA. Transient functional expression of ανβ3 on vascular cells during wound repair. Am J Pathol 1996; 148: 1407. (Pubitemid 26135885)
106. Dallabrida SM, De Sousa MA, Farrell DH. Expression of antisense to integrin subunit β3 inhibits microvascular endothelial cell capillary tube formation in fibrin. J Biol Chem 2000; 275: 32281.
107. Sahni A, Baker CA, Sporn LA, Francis CW. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost 2000; 83: 736. (Pubitemid 30248524)
108. Sahni A, Sporn LA, Francis CW. Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2. J Biol Chem 1999; 274: 14936. (Pubitemid 129518825)
109. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000; 96: 3772.
110. Thompson WD, Smith EB, Stirk CM, Marshall FI, Stout AJ, Kocchar A. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J Pathol 1992; 168: 47.
111. Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to sub-endothelial extracellular matrix: protection and expression of functional properties. J Clin Invest 1989; 84: 1096. (Pubitemid 19247578)
112. Papaconstantinou ME, Carrell CJ, Pineda AO, et al. Thrombin functions through its RGD sequence in a non-canonical conformation. J Biol Chem 2005; 280: 29393.
113. Tsopanoglou NE, Papaconstantinou M, Flordellis CS, Maragoudakis ME. On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via ανβ3. Thromb Haemost 2004; 92: 846. (Pubitemid 39402919)
114. Smadja DM, Basire A, Amelot A, et al. Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells. J Cell Mol Med 2008; 12: 975. (Pubitemid 351718075)
115. Flynn AN, Buret AG. Proteinase-activated receptor 1 (PAR-1) and cell apoptosis. Apoptosis 2004; 9: 729.
116. Helisch A, Schaper W. Arteriogenesis: the development and growth of collateral arteries. Microcirculation 2003; 10: 83-97. (Pubitemid 39004238)
117. Katsanos K, Karnabatidis D, Diamantopoulos A, et al. Thrombin promotes arteriogenesis and hemodynamic recovery in a rabbit hindlimb ischemia model. J Vasc Surg 2009; 49: 1000.
118. Dimitropoulou C, Maragoudakis ME, Konerding MA. Effects of thrombin and of the phospholipase C inhibitor, D609, on the vascularity of the chick chorioallontoic membrane. Gen Pharmacol 2002; 35: 241.
119. De Paula EV, Nascimento MC, Ramos CD, et al. Early in vivo anticoagulation inhibits the angiogenic response following hindlimb ischemia in a rodent model. Thromb Haemost 2006; 96: 68.
120. Chekanov VS, Rayel R, Nikolaychik V, et al. Direct fibrin injection to promote new collateral growth in hind limb ischemia in a rabbit model. J Card Surg 2002; 17: 502. (Pubitemid 36308365)
121. Nash GF, Walsh DC, Kakkar AK. The role of the coagulation system in tumor angiogenesis. Lancet Oncol 2001; 2: 608.
122. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10: 355. (Pubitemid 44693468)
123. Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Sem Thromb Hemost 2007; 33: 688. (Pubitemid 350157013)
124. Petralia GA, Kakkar AK. Treatment of venous thromboembolism in cancer patients. Sem Thromb Hemost 2007; 33: 707.
125. Hamnahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 10: 355.
126. Martin CB, Mahon GM, Klinger MB, et al. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene 2001; 20: 1953.
127. Wojtukiewicz MZ, Tang DG, Ben-Joset E, Renaud C, Walz DA, Honn KV. Solid tumor cells express functional "tethered ligand" thrombin receptor. Cancer Res 1995; 55: 698.
128. Even-Ram SC, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998; 4: 909. (Pubitemid 28364029)
129. Nierodzik ML, Kajumo F, Karpatkin S. Effects of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and metastasis in vivo. Cancer Res 1992; 52: 3267.
130. Fischer EG, Wolfram R, Mueller BM. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 1995; 55: 1629.
131. Nierodzik ML, Chen K, Takeshita K, Karpatkin S. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998; 92: 3694. (Pubitemid 28525196)
132. Zain J, Huang Y, Feng XS, Nierodzik ML, Li J-J, Karpatkin S. Concentration-dependent dual effects of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 2000; 95: 3133. (Pubitemid 30321164)
133. Even-Ram SC, Maoz M, Pokroy E, et al. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha v beta 5 integrin. J Biol Chem 2001; 276: 10952. (Pubitemid 38089274)
134. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003; 162: 1503. (Pubitemid 36512832)
135. Zania P, Kritikou S, Flordellis CS, Maragoudakis ME, Tsopanoglou NE. Blockage of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J Pharmacol Exp Ther 2006; 318: 246. (Pubitemid 43920762)